Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
Back to event

Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)

By Justice Department, Drug Enforcement Administration · Nov 9, 2026, 11:00 PM CST

Read full article at Federal Register
The Drug Enforcement Administration (DEA) is adjusting the 2026 aggregate production quota for the schedule II controlled substances d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). In making this determination, DEA has considered the factors set forth in 21 CFR 1303.13(b) in accordance with 21 U.S.C. 826(a) and is expediting publication of this determinati

Excerpt shown under fair-use limits. Full text remains with the original publisher.

Layer 1 · Claims & fact checks

AI analysis

Layer 2 · Biblical perspective

Biblical interpretation
INSUFFICIENT CONTEXT
Read the biblical analysis

Layer 3 · Reporting analysis

AI analysis

FormalThe statement uses formal, bureaucratic language to convey an official regulatory action.

CitationThe passage cites specific statutes and regulations to legitimize the action and demonstrate compliance.

Context

AI analysis

Missing context

The announcement does not provide the specific quota amounts, the reasons for the adjustment, the expected impact on manufacturers or patients, or any stakeholder input.

Important context

The adjustment follows statutory requirements (21 CFR 1303.13(b), 21 U.S.C. 826) that guide DEA's quota-setting process for schedule II substances, which are tightly regulated due to their potential for abuse.

Opinion vs. reporting

AI analysis

The text is purely factual reporting of an agency action; it contains no opinion.